Journal of diabetes and its complications最新文献

{"title":"Current primary care approaches to diabetic foot prevention and treatment","authors":"Mahmoud Ibrahim ,&nbsp;Ebtesam M. Ba-Essa ,&nbsp;Asma Ahmed ,&nbsp;David G. Armstrong ,&nbsp;Mario Barmaki ,&nbsp;Avivit Cahn ,&nbsp;Kevin Cassar ,&nbsp;Omer Hamtzany ,&nbsp;José Luis Lázaro Martínez ,&nbsp;Helard Manrique ,&nbsp;Omar Mobarak ,&nbsp;Ashu Rastogi ,&nbsp;Manfredi Rizzo ,&nbsp;Shehla Shaikh ,&nbsp;Guillermo E. Umpierrez","doi":"10.1016/j.jdiacomp.2025.109231","DOIUrl":"10.1016/j.jdiacomp.2025.109231","url":null,"abstract":"<div><div>Diabetes-related foot disease is a significant source of morbidity and mortality among people with diabetes, affecting approximately 1.8 % of the global population and leading to many hospital admissions and non-traumatic amputations. Structured multidisciplinary care for the management of diabetes-related foot disease has been shown to reduce complication rates. The role of primary care providers is crucial in the education, recognition, management, and referral of people with diabetes-related foot disease. This evidence-based review article combines expert opinion with research-based consensus to offer comprehensive yet actionable guidance for primary care providers. It discusses the different domains of care for diabetes-related foot disease, including prevention, cardiometabolic biomarkers, education, risk stratification, complication detection, disease staging, treatment options, and management considerations for different geographic populations.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109231"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145614948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence-based validation of cardiovascular benefits from novel MRAs in type 2 diabetes: A meta-analysis of over 30,000 patients","authors":"Qi Fan ,&nbsp;Guoqiang Qin ,&nbsp;Bingyu Du ,&nbsp;Mengfan Kan ,&nbsp;Mengyuan Li ,&nbsp;Qiu Li ,&nbsp;Zhongwen Zhang","doi":"10.1016/j.jdiacomp.2025.109236","DOIUrl":"10.1016/j.jdiacomp.2025.109236","url":null,"abstract":"<div><h3>Aim</h3><div>To evaluate the clinical efficacy and explore the potential mechanisms of novel mineralocorticoid receptor antagonists (MRAs) in reducing the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM).</div></div><div><h3>Methods</h3><div>Randomized controlled trials (RCTs), including relevant subgroup analyses, of steroidal MRAs (eplerenone, canrenone) and non-steroidal MRAs (finerenone, esaxerenone) in T2DM patients were identified through systematic searches of English and Chinese databases. Meta-analysis was performed to assess clinical outcomes, and network pharmacology was used to explore underlying molecular mechanisms.</div></div><div><h3>Result</h3><div>18 RCTs (including relevant subgroup analyses) involving 30,103 participants were included. MRAs significantly reduced MACE risk (OR = 0.81, 95 % CI: 0.75–0.86; <em>P</em> &lt; 0.00001). MRAs also significantly decreased cardiovascular mortality (OR = 0.86, 95 % CI: 0.77–0.97; <em>P</em> = 0.01) and hospitalization for heart failure (OR = 0.77, 95 % CI: 0.68–0.87; <em>P</em> &lt; 0.0001). Network pharmacology identified that steroidal MRAs mainly act via IL-17 and relaxin signaling pathways, targeting MAPK10, GSK3B, PTGS2, NOS2, and MMP1. Non-steroidal MRAs primarily modulate Ras and relaxin pathways, involving targets such as EGFR and PIK3C.</div></div><div><h3>Conclusions</h3><div>This study provides high-certainty evidence supporting MRAs in reducing MACE and heart failure hospitalization, and moderate-certainty evidence for benefits on cardiovascular mortality. Cardioprotective effects may involve Ras, IL-17, and relaxin signaling.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109236"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The miR-200 family in type 2 diabetes: therapeutic and biomarker perspectives","authors":"Toluwalope Esther Ajonijebu ,&nbsp;Sithandiwe Eunice Mazibuko-Mbeje","doi":"10.1016/j.jdiacomp.2025.109211","DOIUrl":"10.1016/j.jdiacomp.2025.109211","url":null,"abstract":"<div><div>MicroRNAs (miRNAs) are critical regulators of gene expression and have emerged as promising biomarkers and therapeutic targets in type 2 diabetes (T2D). Among them, the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) plays key roles in insulin sensitivity, pancreatic β-cell survival, and inflammation. Dysregulation of miR-200a/b and miR-200c has been linked to insulin resistance and β-cell apoptosis, although findings are context dependent, with miR-200c showing both protective and deleterious effects. Therapeutic approaches include the use of antagomiRs to inhibit miR-200a/b (to improve insulin sensitivity) and miR-200c mimics at physiological/ moderate level (to enhance β-cell resilience under oxidative stress). Advances in nanoparticle delivery systems (liposomes, micelles, dendrimers) and chemical modifications such as 2′-<em>O</em>-methyl, 2′-O-methoxyethyl, and locked nucleic acids have improved stability and efficacy, though barriers remain in achieving tissue specificity and minimizing immune activation. In addition to therapy, miR-200 family members are attractive non-invasive biomarkers, with recent studies reporting encouraging sensitivity and specificity for early T2D detection and monitoring of disease progression. However, major challenges persist, including delivery barriers, long-term safety concerns, and limited validation in large, multi-ethnic human cohorts. This review synthesizes current evidence on the dual potential therapeutic strategies of miR-200 inhibition and mimicry, evaluates their biomarker utility, and highlights future directions needed to overcome translational gaps. By addressing these limitations, miR-200-based strategies hold potential to advance toward clinical application in T2D.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109211"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145513051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of a 12-week lifestyle intervention on incretin response during an oral glucose tolerance test in Latino youth with obesity and impaired glucose tolerance","authors":"Jared Rosenberg ,&nbsp;Allison Williams ,&nbsp;Anny Gano ,&nbsp;Molly M. Deak ,&nbsp;Gabriel Q. Shaibi ,&nbsp;Joon Young Kim","doi":"10.1016/j.jdiacomp.2025.109228","DOIUrl":"10.1016/j.jdiacomp.2025.109228","url":null,"abstract":"<div><div>Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the two incretin hormones, play an important pathophysiological role in glucose homeostasis with insulinotropic effects on the pancreatic β-cells. While two previous studies in youth have examined the effects of a lifestyle intervention on incretin concentrations, neither study focused on improvements in glycemic status or oral glucose tolerance test (OGTT)-derived biomarkers. Therefore, we aimed to examine changes in the incretin responses during an OGTT before and after a 12-week lifestyle intervention in Latino youth with obesity and impaired glucose tolerance (IGT). A total of 9 Latino youth with obesity and IGT underwent a two-hour OGTT with 30-min blood samples collected for the measurement of glucose, insulin, and incretin hormones before and after the lifestyle intervention (nutrition education and 180 min of moderate-vigorous exercise weekly for a total of 12 weeks). From pre- to post-intervention, a trend towards reduction was observed in the total GIP area under the curve (AUC) during the OGTT (5499.1 ± 715.3 vs. 4085.2 ± 389.5 pg/mL, <em>p</em> = 0.059), with no change in GLP-1. Moreover, BMI%, glucose AUC, and two-hour glucose concentrations were significantly reduced after the intervention. Our data suggest that a lifestyle intervention in Latino youth with obesity and IGT could influence incretin and glucose metabolism. Future studies should examine if the GIP response to a lifestyle intervention is mediated by baseline glycemic status.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109228"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145604447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of aerobic exercise on cardiometabolic health in patients with diabesity: A systematic review and meta-analysis of randomized controlled trials","authors":"Sameer Badri Al-Mhanna ,&nbsp;Barry A. Franklin ,&nbsp;John M. Jakicic ,&nbsp;Emmanuel Stamatakis ,&nbsp;Linda S. Pescatello ,&nbsp;Deborah Riebe ,&nbsp;Walter R. Thompson ,&nbsp;James S. Skinner ,&nbsp;Sheri R. Colberg ,&nbsp;Jonathan K. Ehrman ,&nbsp;George S. Metsios ,&nbsp;Norsuhana Omar ,&nbsp;Nouf H. Alkhamees ,&nbsp;Bodor Bin Sheeha ,&nbsp;Abdullah F. Alghannam ,&nbsp;Alexios Batrakoulis","doi":"10.1016/j.jdiacomp.2025.109203","DOIUrl":"10.1016/j.jdiacomp.2025.109203","url":null,"abstract":"<div><h3>Purpose</h3><div>This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the effects of aerobic exercise on cardiometabolic health-related indices in patients with type 2 diabetes and concurrent overweight/obesity (diabesity).</div></div><div><h3>Methods</h3><div>PubMed, Web of Science, Scopus, Science Direct, Cochrane Library, and Google Scholar databases were searched from inception to October 2024. The search strategy included the following keywords: diabetes, aerobic exercise, and endurance training. RCTs comparing aerobic exercise training ≥2 weeks in duration to standard treatment were considered eligible. Participants were adults with diabesity.</div></div><div><h3>Results</h3><div>A total of 1391 middle-aged/older adult patients (55 % females) were included in 34 RCTs. Body mass index [standardized mean differences (SMD) -0.18 kg/m², 95 % confidence intervals (CI) -0.36 to −0.01]. waist circumference (SMD -0.23 cm, 95 % CI -0.44 to −0.03), body fat (SMD -0.30 %, 95 % CI -0.59 to −0.01), fasting blood glucose (SMD -0.49 mmol/L, 95 % CI -0.72 to −0.27), glycated hemoglobin (SMD -0.79 %, 95 % CI -1.17 to −0.41), fasting insulin (SMD -0.44 mIU/L, 95 % CI -0.72 to −0.15), homeostatic model assessment for insulin resistance (SMD -0.72, 95 % CI -1.09 to −0.35), high-density lipoprotein cholesterol (SMD 0.32 mg/dL, 95 % CI 0.01 to 0.63), triglycerides (SMD -0.33 mg/dL, 95 % CI -0.63 to −0.04), and total cholesterol (SMD -0.28 mg/dL, 95 % CI -0.47 to −0.10) improved compared with standard treatment.</div></div><div><h3>Conclusions</h3><div>These results underscore the beneficial role of aerobic exercise as a non-pharmacological intervention in managing and treating patients with diabesity when compared to standard treatment, despite the presence of considerable uncertainty in several outcomes.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109203"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145359892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender differences in the distribution of IDL, LDL, and HDL lipoprotein subfractions in MODY compared to type 2 diabetes: Data from the MODY-Ist study","authors":"Hulya Yilmaz Aydogan ,&nbsp;Deniz Kanca Demirci ,&nbsp;Nurdan Gul ,&nbsp;Fatih Yanar ,&nbsp;Sukran Poyrazoglu ,&nbsp;Seda Gulec Yilmaz ,&nbsp;Mete Bora Tuzuner ,&nbsp;Turgay Isbir ,&nbsp;Oguz Ozturk ,&nbsp;Ilhan Satman","doi":"10.1016/j.jdiacomp.2025.109196","DOIUrl":"10.1016/j.jdiacomp.2025.109196","url":null,"abstract":"<div><h3>Background</h3><div>The distribution of intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions specific to diabetes types and changes under dyslipidemia conditions have been well characterised. Research into the distribution of lipoprotein subfractions in Maturity-Onset Diabetes of the Young (MODY) has hitherto been confined to certain subtypes, with gender-based differences remaining to be elucidated. The objective of this study was to comparatively evaluate the distribution of lipoprotein subfractions according to gender in MODY, T2DM patients, and control groups.</div></div><div><h3>Methods</h3><div>Lipoprotein subfractions in 119 serum samples of the study groups were analyzed using the Lipoprint-System.</div></div><div><h3>Results</h3><div>The midbands of IDL (MID-A to C) in female MODY cases, and the HDL-small fraction in male MODY cases, were found to be lower compared to female and male T2DM cases, respectively. In the T2DM group, age was positively correlated with MID-C and MID-B in both genders, while it was negatively correlated with MID-A in female cases. ROC analysis demonstrated that the decrease in the MID-C fraction in female MODY subjects (AUC:0.809, <em>p</em> = 0.0001) and the decrease in the HDL-small fraction in male MODY subjects (AUC:0.818, <em>p</em> = 0.002) were significantly associated with the likelihood of MODY.</div></div><div><h3>Conclusion</h3><div>Given that a considerable proportion of MODY patients are frequently misdiagnosed as T2DM, low levels of MID-C and HDL-small fractions, both of which are triglyceride-rich, may have potential as a diagnostic value for female and male MODY patients, respectively.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109196"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145417943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the impact of dysphagia on quality of life and determining SWAL-QOL cut-off scores in diabetes mellitus patients: a data mining approach","authors":"Fulden Sari ,&nbsp;Zilan Bazancir-Apaydın ,&nbsp;Süleyman Sari ,&nbsp;Mehmet Can Sari ,&nbsp;Şenol Çelik","doi":"10.1016/j.jdiacomp.2025.109205","DOIUrl":"10.1016/j.jdiacomp.2025.109205","url":null,"abstract":"<div><h3>Aim</h3><div>Swallowing difficulties are increasingly recognized as a significant yet underreported complication of diabetes mellitus (DM), with evidence suggesting that more than 50 % of patients with the condition may be affected. This study aimed to assess the impact of swallowing disorders on the quality of life in DM patients, to identify other factors influencing swallowing disorders, and to determine the cut-off score for the SWAL-QOL questionnaire in these patients using data mining methods.</div></div><div><h3>Methods</h3><div>This cross-sectional study analyzed 150 DM patients, assessing swallowing assessment using the EAT-10, quality of life with the SWAL-QOL, and swallowing difficulty through the Visual Analogue Scale (VAS).</div></div><div><h3>Results</h3><div>Patients with dysphagia exhibited significantly lower scores across multiple SWAL-QOL subgroups-including General Burden, Food Selection, Eating Duration, Eating Desire, Fear of Eating, Sleep, Fatigue, Communication, Mental Health, Social Functioning, and the total SWAL-QOL score compared to non-dysphagic patients (p &lt; 0.001). The Swallowing Difficulty-VAS score was significantly elevated in dysphagic patients (p &lt; 0.001). EAT-10 scores were correlated with Swallowing Difficulty-VAS and SWAL-QOL subgroups, including General Burden, Food Selection, Eating Duration, Eating Desire, Fear of Eating, Sleep, Fatigue, Communication, Mental Health, Social Functioning, and the total score. The SWAL-QOL total score cut-off of 65.7 was identified for DM patients with dysphagia.</div></div><div><h3>Conclusions</h3><div>Close monitoring of these symptoms by clinicians is essential, and targeted rehabilitation interventions are strongly recommended to improve both swallowing function and overall quality of life in this population.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109205"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145359893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study","authors":"Nikolaos Angelopoulos ,&nbsp;Sarantis Livadas ,&nbsp;Ioannis Androulakis ,&nbsp;Valentina Petkova ,&nbsp;Andreas Rizoulis ,&nbsp;Anastasios Boniakos ,&nbsp;Rodis Paparodis ,&nbsp;Ploutarchos Tzoulis ,&nbsp;Voula Mentzelopoulou ,&nbsp;Dimos Florakis ,&nbsp;Evangelos Fousteris ,&nbsp;Areti Korakovouni ,&nbsp;Dimitra Zianni ,&nbsp;Zadalla Mouslech ,&nbsp;Manfredi Rizzo ,&nbsp;Dimitri P. Mikhailidis ,&nbsp;Panagiotis Anagnostis","doi":"10.1016/j.jdiacomp.2025.109181","DOIUrl":"10.1016/j.jdiacomp.2025.109181","url":null,"abstract":"<div><h3>Background/aims</h3><div>Tirzepatide has been approved for weight loss in adults with obesity. However, real-world data are still needed. This real-world prospective study is among the first to evaluate the short-term metabolic effects of low-dose tirzepatide in adults with obesity but without diabetes mellitus (DM). Secondary endpoints included associations between these changes and anthropometric or baseline metabolic parameters.</div></div><div><h3>Methods</h3><div>In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks. Body weight, body mass index (BMI), total (TC), low-density (LDL-C) and high-density lipoprotein cholesterol (HDL-C), triglycerides, fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), and hepatic steatosis index (HSI) were measured at baseline and week 12.</div></div><div><h3>Results</h3><div>Seventy-five participants (mean age 46.9 ± 9.9 years) were included. After 12 weeks, body weight (−8.1 ± 4.3 %) and BMI significantly decreased. TC, LDL-C, triglycerides, FPG, HbA1c, and HSI were significantly reduced and inversely associated with their baseline levels. HbA1c and HSI changes correlated with weight loss. No effect was observed on HDL-C. Statin use had no impact on outcomes.</div></div><div><h3>Conclusion</h3><div>Short-term low-dose tirzepatide improves the lipid profile, HbA1c, and HSI in obese adults without DM, especially in those with abnormal baseline values. Lipid changes occurred independently of weight loss.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109181"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145247846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gestational diabetes mellitus and the subsequent risk of chronic kidney disease: A systematic review and meta-analysis","authors":"Qin Zhou,&nbsp;Hao Yang,&nbsp;Xi-shao Xie,&nbsp;Ren-ding Wang","doi":"10.1016/j.jdiacomp.2025.109197","DOIUrl":"10.1016/j.jdiacomp.2025.109197","url":null,"abstract":"<div><h3>Aims</h3><div>The evidence regarding a relationship between gestational diabetes mellitus (GDM) and the risk of chronic kidney disease (CKD) in later life has been inconsistent. We systematically evaluated whether such an association exists.</div></div><div><h3>Methods</h3><div>We searched the PubMed, Embase, and Cochrane Library databases from their inception to 18 May 2025. Odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated to assess the association between GDM and subsequent CKD.</div></div><div><h3>Results</h3><div>Eight articles involving 21,806,683 pregnant women were included in our meta-analysis. The overall risk of CKD in the GDM group was significantly higher than in the control group (OR = 1.79, 95 % CI = 1.16–2.78, <em>P</em> = 0.009). Further analyses restricted to high-quality studies (OR = 2.75, 95 % CI = 1.68–4.52, <em>P</em> &lt; 0.01, I² = 96.8 %) or to studies adjusting for key confounders (OR = 2.76, 95 % CI = 1.67–4.52, <em>P</em> = 0.001, I² = 65.9 %) also demonstrated a significant association. Most subgroup analysis results were consistent with the overall findings.</div></div><div><h3>Conclusions</h3><div>This systematic review and meta-analysis support a significant association between GDM and future CKD risk, suggesting that GDM may serve as an early warning sign for renal disease. However, confidence in the results was reduced by the considerable heterogeneity and more work is needed to understand this variability.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109197"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145308181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(25)00274-0","DOIUrl":"10.1016/S1056-8727(25)00274-0","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109221"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145526302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}